Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | POLA1 | P09884 | 2/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.31 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.31 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21360719 | 0.89 | OPRM1 (0.74) | OPRM1OPRD1OPRK1SIGMAR1POLA1 | |
| SCHEMBL21360674 | 0.85 | OPRM1 (0.69) | OPRM1OPRD1OPRK1SIGMAR1POLA1 | |
| SCHEMBL22477177 | 0.84 | OPRM1 (0.67) | OPRM1OPRD1OPRK1SIGMAR1POLA1 | |
| SCHEMBL21360675 | 0.84 | OPRM1 (0.67) | OPRM1OPRD1OPRK1SIGMAR1POLA1 | |
| SCHEMBL21360672 | 0.84 | OPRM1 (0.67) | OPRM1OPRD1OPRK1SIGMAR1POLA1 | |
| SCHEMBL21360785 | 0.83 | OPRM1 (0.63) | OPRM1OPRD1OPRK1POLA1KARS1 | |
| SCHEMBL21360822 | 0.83 | OPRM1 (0.63) | OPRM1OPRD1OPRK1POLA1KARS1 | |
| SCHEMBL21360690 | 0.82 | OPRM1 (0.65) | OPRM1OPRD1OPRK1HSP90AA1KARS1 | |
| SCHEMBL21360678 | 0.82 | OPRM1 (0.65) | OPRM1OPRD1OPRK1HSP90AA1KARS1 | |
| Dezocine SCHEMBL21081189 | 0.80 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3401306-B1 | DEZOCINE ANALOGUE | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2020-09-30 | — | — | EP | disclosed |
| US-10414718-B2 | Dezocine analogue | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414718-B2 | Dezocine analogue | DDO, DDC, DAO | OPRM1 9/4885OPRD1 359/4885OPRK1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.